glp 1 agonist weight loss mechanism Mechanisms by which GLP-1 agonists may exert beneficial effects on the GLP-1 mechanism of action. Glucagon-like

Adipose tissue inflammation and metabolic dysfunction in obesity

A few GLP-1 agonists currently in phase 3 trials are higher-dose injectable semaglutide 7.2 mg (Novo Nordisk), oral semaglutide 50 mg (Novo Nordisk) and orforglipron (Eli Lilly)

(2020, March)

drink a lot of alcohol and abruptly stop drinking, or use medicines called sedatives (these make you sleepy), benzodiazepines, or antiseizure medicines and stop using them all of a sudden

However, these prescription treatments often carry significant costs and may cause side effects such as nausea and digestive discomfort, limiting their suitability for some individuals